Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 114, Issue 1-2, 2009, Pages 8-20

  Clarke, Robert ^a,b   Shajahan, Ayesha N ^a   Riggins, Rebecca B ^a   Cho, Younsook ^a   Crawford, Anatasha ^a   Xuan, Jianhua ^c   Wang, Yue ^c   Zwart, Alan ^a   Nehra, Ruchi ^a   Liu, Minetta C ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c State University   (United States)

Author keywords

Antiestrogen; Apoptosis; Autophagy; Breast cancer; Cell signaling; Endoplasmic reticulum; Estrogens; Gene networks; Unfolded protein response

Indexed keywords

BECLIN 1; DANSYLCADAVERINE; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; NUCLEOPHOSMIN; PROTEIN BCL 2; PROTEIN P62; X BOX BINDING PROTEIN 1;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER HORMONE THERAPY; CELL FATE; GENE EXPRESSION; HORMONE RESPONSE; HUMAN; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; INTERFERON REGULATORY FACTOR-1; MEMBRANE PROTEINS; NF-KAPPA B; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 63149172095     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.12.023     Document Type: Article

References (160)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics, 2006. CA Cancer J. Clin. 56 (2006) 106-130
2. Foulkes W.D., Metcalfe K., Sun P., Hanna W.M., Lynch H.T., Ghadirian P., Tung N., Olopade O.I., Weber B.L., McLennan J., Olivotto I.A., Begin L.R., and Narod S.A. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res. 10 (2004) 2029-2034
3. Thorpe S.M. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. Acta Oncol. 27 (1988) 1-19
4. Foulkes W.D. Re: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J. Natl. Cancer Inst. 96 (2004) 1040-1041
5. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of randomised trials. Lancet 352 (1998) 930-942
6. Fisher B., Dignam J., Mamounas E.P., Costantino J.P., Wickerham D.L., Redmond C., Wolmark N., Dimitrov N.V., Bowman D.M., Glass A.G., Atkins J.L., Abramson N., Sutherland C.M., Aron B.S., and Margolese R.G. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen-receptor-negative tumors: eight year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J. Clin. Oncol. 14 (1996) 1982-1992
7. Mansour E.G., Gray R., Shatila A.H., Tormey D.C., Cooper M.R., Osborne C.K., and Falkson G. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis-an intergroup study. J. Clin. Oncol. 16 (1998) 3486-3492
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351 (1998) 1451-1467
9. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 399 (1992) 1-15
10. Clarke R., Leonessa F., Welch J.N., and Skaar T.C. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53 (2001) 25-71
11. Cole M.P., Jones C.T.A., and Todd I.D.H. A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br. J. Cancer 25 (1971) 270-275
12. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., Norton L., Nickelsen T., Bjarnson N.H., Morrow M., Lippman M.E., Black D., Glusman J.E., Costa A., and Jordan V.C. The effect of raloxifene on risk of breast cancer in postmenopausal women; results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J. Am. Med. Assoc. 281 (1999) 2189-2197
13. Howell A., DeFriend D., Robertson J.F.R., Blamey R.W., and Walton P. Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 345 (1995) 29-30
14. Howell A., Robertson J.F., Quaresma A.J., Aschermannova A., Mauriac L., Kleeberg U.R., Vergote I., Erikstein B., Webster A., and Morris C. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 20 (2002) 3396-3403
15. Ferretti G., Bria E., Giannarelli D., Felici A., Papaldo P., Fabi A., Di C.S., Ruggeri E.M., Milella M., Ciccarese M., Cecere F.L., Gelibter A., Nuzzo C., Cognetti F., Terzoli E., and Carlini P. Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br. J. Cancer 94 (2006) 1789-1796
16. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Rabaglio M., Smith I., Wardley A., Price K.N., and Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 (2005) 2747-2757
17. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., Bajetta E., Dodwell D., Coleman R.E., Fallowfield L.J., Mickiewicz E., Andersen J., Lonning P.E., Cocconi G., Stewart A., Stuart N., Snowdon C.F., Carpentieri M., Massimini G., and Bliss J.M. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
18. Boccardo F., Rubagotti A., Amoroso D., Mesiti M., Romeo D., Caroti C., Farris A., Cruciani G., Villa E., Schieppati G., and Mustacchi G. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J. Clin. Oncol. 19 (2001) 4209-4215
19. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., Hilfrich J., Kwasny W., Menzel C., Samonigg H., Seifert M., Gademann G., Kaufmann M., and Wolfgang J. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
20. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., and Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
21. Bonneterre J., Buzdar A., Nabholtz J.M., Robertson J.F., Thurlimann B., von Euler M., Sahmoud T., Webster A., and Steinberg M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92 (2001) 2247-2258
22. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Janicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Lassus M., Verbeek J.A., Staffler B., Chaudri-Ross H.A., and Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase iii study of the international letrozole breast cancer group. J. Clin. Oncol. 19 (2001) 2596-2606
23. Clarke R., and Brünner N. Cross resistance and molecular mechanisms in antiestrogen resistance. Endocr. Relat. Cancer 2 (1995) 59-72
24. Osipo C., Gajdos C., Liu H., Chen B., and Jordan V.C. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J. Natl. Cancer Inst. 95 (2003) 1597-1608
25. Gottardis M.M., and Jordan V.C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48 (1988) 5183-5187
26. Osborne C.K., Coronado E.B., and Robinson J.P. Human breast cancer in athymic nude mice: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol. 23 (1987) 1189-1196
27. Brünner N., Frandsen T.L., Holst-Hansen C., Bei M., Thompson E.W., Wakeling A.E., Lippman M.E., and Clarke R. MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant which retains sensitivity to the steroidal antiestrogen ICI 182, 780. Cancer Res. 53 (1993) 3229-3232
28. Brünner N., Boysen B., Jirus S., Skaar T.C., Holst-Hansen C., Lippman J., Frandsen T., Spang-Thomsen M., Fuqua S.A.W., and Clarke R. MCF7/LCC9: an antiestrogen resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182, 780 confers an early crossresistance to the non-steroidal antiestrogen tamoxifen. Cancer Res. 57 (1997) 3486-3493
29. Clarke R., Liu M.C., Bouker K.B., Gu Z., Lee R.Y., Zhu Y., Skaar T.C., Gomez B., O'Brien K., Wang Y., and Hilakivi-Clarke L.A. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22 (2003) 7316-7339
30. Nomura Y., Tashiro H., and Hisamatsu K. Differential effects of estrogen and antiestrogen on in vitro clonogenic growth of human breast cancers in soft agar. J. Natl. Cancer Inst. 82 (1990) 1146-1149
31. Haddow A., Watkins J.M., and Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. Br. Med. J. 2 (1944) 393-398
32. Walpole A.L., and Paterson E. Synthetic oestrogens in mammary cancer. Lancet 2 (1949) 783-789
33. Clarke R., van den Berg H.W., and Murphy R.F. Tamoxifen and 17β-estradiol reduce the membrane fluidity of human breast cancer cells. J. Natl. Cancer Inst. 82 (1990) 1702-1705
34. Pattingre S., and Levine B. Bcl-2 inhibition of autophagy: a new route to cancer?. Cancer Res. 66 (2006) 2885-2888
35. Riggins R., Bouton A.H., Liu M.C., and Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam. Horm. 71 (2005) 201-237
36. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., Packer M., Schneider M.D., and Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122 (2005) 927-939
37. Zhivotovsky B., and Kroemer G. Apoptosis and genomic instability. Nat. Rev. Mol. Cell Biol. 5 (2004) 752-762
38. Brown J.M., and Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer 5 (2005) 231-237
39. Goldstein J.C., Waterhouse N.J., Juin P., Evan G.I., and Green D.R. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat. Cell Biol. 2 (2000) 156-162
40. Shimizu S., Kanaseki T., Mizushima N., Mizuta T., Rakawa-Kobayashi S., Thompson C.B., and Tsujimoto Y. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 6 (2004) 1221-1228
41. Lamparska-Przybysz M., Gajkowska B., and Motyl T. BID-deficient breast cancer MCF-7 cells as a model for the study of autophagy in cancer therapy. Autophagy 2 (2006) 47-48
42. Furuya N., Yu J., Byfield M., Pattingre S., and Levine B. The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function. Autophagy 1 (2005) 46-52
43. Liang X.H., Jackson S., Seaman M., Brown K., Kempkes B., Hibshoosh H., and Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402 (1999) 672-676
44. Edinger A.L., and Thompson C.B. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 16 (2004) 663-669
45. Broker L.E., Kruyt F.A., and Giaccone G. Cell death independent of caspases: a review. Clin. Cancer Res. 11 (2005) 3155-3162
46. Mizushima N., and Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 3 (2007) 542-545
47. Kimura S., Noda T., and Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3 (2007) 452-460
48. Klionsky D.J., Abeliovich H., Agostinis P., Agrawal D.K., Aliev G., Askew D.S., Baba M., Baehrecke E.H., Bahr B.A., Ballabio A., Bamber B.A., Bassham D.C., Bergamini E., Bi X., Biard-Piechaczyk M., Blum J.S., Bredesen D.E., Brodsky J.L., Brumell J.H., Brunk U.T., Bursch W., Camougrand N., Cebollero E., Cecconi F., Chen Y., Chin L.S., Choi A., Chu C.T., Chung J., Clarke P.G., Clark R.S., Clarke S.G., Clave C., Cleveland J.L., Codogno P., Colombo M.I., Coto-Montes A., Cregg J.M., Cuervo A.M., Debnath J., Demarchi F., Dennis P.B., Dennis P.A., Deretic V., Devenish R.J., Di S.F., Dice J.F., Difiglia M., Nesh-Kumar S., Distelhorst C.W., Djavaheri-Mergny M., Dorsey F.C., Droge W., Dron M., Dunn Jr. W.A., Duszenko M., Eissa N.T., Elazar Z., Esclatine A., Eskelinen E.L., Fesus L., Finley K.D., Fuentes J.M., Fueyo J., Fujisaki K., Galliot B., Gao F.B., Gewirtz D.A., Gibson S.B., Gohla A., Goldberg A.L., Gonzalez R., Gonzalez-Estevez C., Gorski S., Gottlieb R.A., Haussinger D., He Y.W., Heidenreich K., Hill J.A., Hoyer-Hansen M., Hu X., Huang W.P., Iwasaki A., Jaattela M., Jackson W.T., Jiang X., Jin S., Johansen T., Jung J.U., Kadowaki M., Kang C., Kelekar A., Kessel D.H., Kiel J.A., Kim H.P., Kimchi A., Kinsella T.J., Kiselyov K., Kitamoto K., Knecht E., Komatsu M., Kominami E., Kondo S., Kovacs A.L., Kroemer G., Kuan C.Y., Kumar R., Kundu M., Landry J., Laporte M., Le W., Lei H.Y., Lenardo M.J., Levine B., Lieberman A., Lim K.L., Lin F.C., Liou W., Liu L.F., Lopez-Berestein G., Lopez-Otin C., Lu B., Macleod K.F., Malorni W., Martinet W., Matsuoka K., Mautner J., Meijer A.J., Melendez A., Michels P., Miotto G., Mistiaen W.P., Mizushima N., Mograbi B., Monastyrska I., Moore M.N., Moreira P.I., Moriyasu Y., Motyl T., Munz C., Murphy L.O., Naqvi N.I., Neufeld T.P., Nishino I., Nixon R.A., Noda T., Nurnberg B., Ogawa M., Oleinick N.L., Olsen L.J., Ozpolat B., Paglin S., Palmer G.E., Papassideri I., Parkes M., Perlmutter D.H., Perry G., Piacentini M., Pinkas-Kramarski R., Prescott M., Proikas-Cezanne T., Raben N., Rami A., Reggiori F., Rohrer B., Rubinsztein D.C., Ryan K.M., Sadoshima J., Sakagami H., Sakai Y., Sandri M., Sasakawa C., Sass M., Schneider C., Seglen P.O., Seleverstov O., Settleman J., Shacka J.J., Shapiro I.M., Sibirny A., Silva-Zacarin E.C., Simon H.U., Simone C., Simonsen A., Smith M.A., Spanel-Borowski K., Srinivas V., Steeves M., Stenmark H., Stromhaug P.E., Subauste C.S., Sugimoto S., Sulzer D., Suzuki T., Swanson M.S., Tabas I., Takeshita F., Talbot N.J., Talloczy Z., Tanaka K., Tanaka K., Tanida I., Taylor G.S., Taylor J.P., Terman A., Tettamanti G., Thompson C.B., Thumm M., Tolkovsky A.M., Tooze S.A., Truant R., Tumanovska L.V., Uchiyama Y., Ueno T., Uzcategui N.L., van I d.K., Vaquero E.C., Vellai T., Vogel M.W., Wang H.G., Webster P., Wiley J.W., Xi Z., Xiao G., Yahalom J., Yang J.M., Yap G., Yin X.M., Yoshimori T., Yu L., Yue Z., Yuzaki M., Zabirnyk O., Zheng X., Zhu X., and Deter R.L. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4 (2008) 151-175
49. Yousefi S., Perozzo R., Schmid I., Ziemiecki A., Schaffner T., Scapozza L., Brunner T., and Simon H.U. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat. Cell Biol. 8 (2006) 1124-1132
50. Jin S. Autophagy, mitochondrial quality control, and oncogenesis. Autophagy 2 (2006) 80-84
51. Park M.A., Yacoub A., Sarkar D., Emdad L., Rahmani M., Spiegel S., Koumenis C., Graf M., Curiel D.T., Grant S., Fisher P.B., and Dent P. PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy 4 (2008)
52. Yacoub A., Park M.A., Gupta P., Rahmani M., Zhang G., Hamed H., Hanna D., Sarkar D., Lebedeva I.V., Emdad L., Sauane M., Vozhilla N., Spiegel S., Koumenis C., Graf M., Curiel D.T., Grant S., Fisher P.B., and Dent P. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol. Cancer Ther. 7 (2008) 297-313
53. Chen Y., Millan-Ward E., Kong J., Israels S.J., and Gibson S.B. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ. 15 (2008) 171-182
54. Yan C.H., Yang Y.P., Qin Z.H., Gu Z.L., Reid P., and Liang Z.Q. Autophagy is involved in cytotoxic effects of crotoxin in human breast cancer cell line MCF-7 cells. Acta Pharmacol. Sin. 28 (2007) 540-548
55. Guillon-Munos A., van Bemmelen M.X., and Clarke P.G. Autophagy can be a killer even in apoptosis-competent cells. Autophagy 2 (2006) 140-142
56. Apel A., Herr I., Schwarz H., Rodemann H.P., and Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res. 68 (2008) 1485-1494
57. Li M., Jiang X., Liu D., Na Y., Gao G.F., and Xi Z. Autophagy protects LNCaP cells under androgen deprivation conditions. Autophagy 4 (2008) 54-60
58. Boya P., Gonzalez-Polo R.A., Casares N., Perfettini J.L., Dessen P., Larochette N., Metivier D., Meley D., Souquere S., Yoshimori T., Pierron G., Codogno P., and Kroemer G. Inhibition of macroautophagy triggers apoptosis. Mol. Cell Biol. 25 (2005) 1025-1040
59. Castedo M., Perfettini J.L., Roumier T., Valent A., Raslova H., Yakushijin K., Horne D., Feunteun J., Lenoir G., Medema R., Vainchenker W., and Kroemer G. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 23 (2004) 4362-4370
60. Roninson I.B., Broude E.V., and Chang B.D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. 4 (2001) 303-313
61. Kops G.J., Weaver B.A., and Cleveland D.W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 5 (2005) 773-785
62. Kanduc D., Mittelman A., Serpico R., Sinigaglia E., Sinha A.A., Natale C., Santacroce R., Di Corcia M.G., Lucchese A., Dini L., Pani P., Santacroce S., Simone S., Bucci R., and Farber E. Cell death: apoptosis versus necrosis. Int. J. Oncol. 21 (2002) 165-170
63. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., and Pereira-Smith O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9363-9367
64. Wright W.E., Pereira-Smith O.M., and Shay J.W. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol. Cell Biol. 9 (1989) 3088-3092
65. Bouker K.B., Skaar T.C., Fernandez D.R., O'Brien K.A., and Clarke R. Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182, 780 (Faslodex, Fulvestrant). Cancer Res. 64 (2004) 4030-4039
66. Kyprianou N., English H.F., Davidson N.E., and Isaacs J.T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res. 51 (1991) 162-166
67. El Etreby M.F., Liang Y., Wrenn R.W., and Schoenlein P.V. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 51 (1998) 149-168
68. Gaddy V.T., Barrett J.T., Delk J.N., Kallab A.M., Porter A.G., and Schoenlein P.V. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin. Cancer Res. 10 (2004) 5215-5225
69. Bursch W., Ellinger A., Kienzl H., Torok L., Pandey S., Sikorska M., Walker R., and Hermann R.S. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 17 (1996) 1595-1607
70. Inbal B., Bialik S., Sabanay I., Shani G., and Kimchi A. DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J. Cell Biol. 157 (2002) 455-468
71. Qadir M.A., Kwok B., Dragowska W.H., To K.H., Le D., Bally M.B., and Gorski S.M. Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res. Treat. 3 (2008) 389-403
72. Bjorkoy G., Lamark T., Brech A., Outzen H., Perander M., Overvatn A., Stenmark H., and Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 171 (2005) 603-614
73. Ichimura Y., Kumanomidou T., Sou Y.S., Mizushima T., Ezaki J., Ueno T., Kominami E., Yamane T., Tanaka K., and Komatsu M. Structural basis for sorting mechanism of p62 in selective autophagy. J. Biol. Chem. 283 (2008) 22847-22857
74. Ichimura Y., Kominami E., Tanaka K., and Komatsu M. Selective turnover of p62/A170/SQSTM1 by autophagy. Autophagy 4 (2008)
75. Riggins R., Zwart A., Nehra N., Agarwal P., and Clarke R. The NFκB inhibitor parthenolide restores ICI 182, 780 (Faslodex; Fulvestrant)-induced apoptosis in antiestrogen resistant breast cancer cells. Mol. Cancer Ther. 4 (2005) 33-41
76. Gomez B.P., Riggins R., Shajahan A.N., Klimach U., Wang A., Crawford A.C., Zhu Y., Zwart A., Wang M., and Clarke R. Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J. 21 (2007) 4013-4027
77. Clarke R., Brünner N., Katzenellenbogen B.S., Thompson E.W., Norman M.J., Koppi C., Paik S., Lippman M.E., and Dickson R.B. Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 3649-3653
78. Clarke R., Brünner N., Thompson E.W., Glanz P., Katz D., Dickson R.B., and Lippman M.E. The inter-relationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer. J. Endocrinol. 122 (1989) 331-340
79. Cameron D.A., Keen J.C., Dixon J.M., Bellamy C., Hanby A., Anderson T.J., and Miller W.R. Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. Eur. J. Cancer 36 (2000) 845-851
80. Reimer T., Koczan D., Muller H., Friese K., Thiesen H.J., and Gerber B. Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer. Breast Cancer Res. 4 (2002) R9
81. Ellis P.A., Smith I.E., Detre S., Burton S.A., Salter J., A'Hern R., Walsh G., Johnston S.R., and Dowsett M. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res. Treat. 48 (1998) 107-116
82. Brunner N., Boulay V., Fojo A., Freter C.E., Lippman M.E., and Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res. 53 (1993) 283-290
83. Clarke R., Ressom H.W., Wang A., Xuan J., Liu M.C., Gehan E.A., and Wang Y. The properties of very high dimensional data spaces: implications for exploring gene and protein expression data. Nat. Rev. Cancer 8 (2008) 37-49
84. Wang Y., Miller D.J., and Clarke R. Approaches to working in high-dimensional data spaces: gene expression microarrays. Br. J. Cancer 98 (2008) 1023-1028
85. Clarke R., Skaar T.C., Bouker K.B., Davis N., Lee Y.R., Welch J.N., and Leonessa F. Molecular and pharmacological aspects of antiestrogen resistance. J. Steroid Biochem. Mol. Biol. 76 (2001) 71-84
86. Clarke R., and Brünner N. Acquired estrogen independence and antiestrogen resistance in breast cancer: estrogen receptor-driven phenotypes?. Trends Endocrinol. Metab. 7 (1996) 25-35
87. Huang S. Genomics, complexity and drug discovery: insights from Boolean network models of cellular regulation. Pharmacogenomics 2 (2001) 203-222
88. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Cameron D.A., Palmer M.J., and Pater J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J. Natl. Cancer Inst. 97 (2005) 1262-1271
89. Hashimoto R.F., Kim S., Shmulevich I., Zhang W., Bittner M.L., and Dougherty E.R. Growing genetic regulatory networks from seed genes. Bioinformatics 20 (2004) 1241-1247
90. Wang C., Xuan J., Chen L., Zhao P., Wang Y., Clarke R., and Hoffman E. Motif-directed component analysis for regulatory network inference. BMC Bioinform. 9 (2008) 10.1186/1471-2105-9-S1-S21
91. Zhang Y., Xuan J., de Los Reyes B.G., Clarke R., and Ressom H.W. Network motif-based identification of transcription factor-target gene relationships by integrating multi-source biological data. BMC Bioinform. 9 (2008) 203
92. Jeffery I.B., Madden S.F., McGettigan P.A., Perriere G., Culhane A.C., and Higgins D.G. Integrating transcription factor binding site information with gene expression datasets. Bioinformatics 23 (2007) 298-305
93. L. Chen, J. Xuan, C. Wang, L.-M. Shih, Y. Wang, Z. Zhang, E.P. Hoffman, R. Clarke, Knowledge guided multi-scale independent component analysis for biomarker identification, BMC Bioinform. 9 (2008), doi:10.1186/1471-2105-9-416.
94. McKenzie S., and Kyprianou N. Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J. Cell Biochem. 97 (2006) 18-32
95. Gu Z., Lee R.Y., Skaar T.C., Bouker K.B., Welch J.N., Lu J., Liu A., Zhu Y., Davis N., Leonessa F., Brunner N., Wang Y., and Clarke R. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to faslodex (ICI 182, 780). Cancer Res. 62 (2002) 3428-3437
96. Bouker K.B., Skaar T.C., Riggins R., Harburger D.S., Fernandez D.R., Zwart A., Wang A., and Clarke R. Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 26 (2005) 1527-1535
97. Bouker K.B., Skaar T.C., Harburger D.S., Riggins R., Fernandez D.R., Zwart A., and Clarke R. The A4396G polymorphism in interferon regulatory factor-1 is frequently expressed in breast cancer. Cancer Genet. Cytogenet. 175 (2007) 61-64
98. Ron D. Translational control in the endoplasmic reticulum stress response. J. Clin. Invest. 110 (2002) 1383-1388
99. Zhang K., and Kaufman R.J. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 66 (2006) S102-S109
100. DuRose J.B., Tam A.B., and Niwa M. Intrinsic capacities of molecular sensors of the unfolded protein response to sense alternate forms of endoplasmic reticulum stress. Mol. Biol. Cell 17 (2006) 3095-3107
101. Yoshida H., Matsui T., Yamamoto A., Okada T., and Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107 (2001) 881-891
102. Ogata M., Hino S., Saito A., Morikawa K., Kondo S., Kanemoto S., Murakami T., Taniguchi M., Tanii I., Yoshinaga K., Shiosaka S., Hammarback J.A., Urano F., and Imaizumi K. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol. Cell Biol. 26 (2006) 9220-9231
103. Feldman D.E., Chauhan V., and Koong A.C. The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol. Cancer Res. 3 (2005) 597-605
104. Clauss I.M., Chu M., Zhao J.L., and Glimcher L.H. The basic domain/leucine zipper protein hXBP-1 preferentially binds to and transactivates CRE-like sequences containing an ACGT core. Nucleic Acids Res. 24 (1996) 1855-1864
105. Liou H.C., Boothby M.R., Finn P.W., Davidon R., Nabavi N., Zeleznik L., Ting J.P., and Glimcher L.H. A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science 247 (1990) 1581-1584
106. Sriburi R., Jackowski S., Mori K., and Brewer J.W. XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J. Cell Biol. 167 (2004) 35-41
107. Lee A.H., Iwakoshi N.N., Anderson K.C., and Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 9946-9951
108. Ding L., Yan J., Zhu J., Zhong H., Lu Q., Wang Z., Huang C., and Ye Q. Ligand-independent activation of estrogen receptor alpha by XBP-1. Nucleic Acids Res. 31 (2003) 5266-5274
109. Reimold A.M., Iwakoshi N.N., Manis J., Vallabhajosyula P., Szomolanyi-Tsuda E., Gravallese E.M., Friend D., Grusby M.J., Alt F., and Glimcher L.H. Plasma cell differentiation requires the transcription factor XBP-1. Nature 412 (2001) 300-307
110. Clauss I.M., Gravallese E.M., Darling J.M., Shapiro F., Glimcher M.J., and Glimcher L.H. In situ hybridization studies suggest a role for the basic region-leucine zipper protein hXBP-1 in exocrine gland and skeletal development during mouse embryogenesis. Dev. Dyn. 197 (1993) 146-156
111. Reimold A.M., Etkin A., Clauss I., Perkins A., Friend D.S., Zhang J., Horton H.F., Scott A., Orkin S.H., Byrne M.C., Grusby M.J., and Glimcher L.H. An essential role in liver development for transcription factor XBP-1. Genes Dev. 14 (2000) 152-157
112. Wang D.Y., Fulthorpe R., Liss S.N., and Edwards E.A. Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol. Endocrinol. 18 (2004) 402-411
113. Tozlu S., Girault I., Vacher S., Vendrell J., Andrieu C., Spyratos F., Cohen P., Lidereau R., and Bieche I. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr. Relat. Cancer 13 (2006) 1109-1120
114. Willman C.L., Sever C.E., Pallavicini M.G., Harada H., Tanaka N., Slovak M.L., Yamamoto H., Harada K., Meeker T.C., List A.F., and Taniguchi T. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259 (1993) 965-971
115. van den Berg H.W., Leahey W.J., Lynch M., Clarke R., and Nelson J. Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitises them to the anti-proliferative effects of tamoxifen. Br. J. Cancer 55 (1987) 255-257
116. Matsuyama T., Kimura T., Kitagawa M., Pfeffer K., Kawakami T., Watanabe N., Kundig T.M., Amakawa R., Kishihara K., Wakeham A., Potter J., Furlonger C.L., Narendran A., Suzuki H., Ohashi P.S., Paige C.J., Taniguchi T., and Mak T.W. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75 (1993) 83-97
117. Namiki S., Nakamura T., Oshima S., Yamazaki M., Sekine Y., Tsuchiya K., Okamoto R., Kanai T., and Watanabe M. IRF-1 mediates upregulation of LMP7 by IFN-gamma and concerted expression of immunosubunits of the proteasome. FEBS Lett. 579 (2005) 2781-2787
118. Lee S.H., Kim J.W., Oh S.H., Kim Y.J., Rho S.B., Park K., Park K.L., and Lee J.H. IFN-gamma/IRF-1-induced p27kip1 down-regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer. FEBS Lett. 579 (2005) 1027-1033
119. Lee S.H., Kim J.W., Lee H.W., Cho Y.S., Oh S.H., Kim Y.J., Jung C.H., Zhang W., and Lee J.H. Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-gamma induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression. Oncogene 22 (2003) 381-391
120. Tamura T., Ishihara M., Lamphier M.S., Tanaka N., Oishi I., Alzawa S., Matsuyama T., Mak T.W., Taki S., and Taniguchi T. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 376 (1995) 596-599
121. Prost S., Bellamy C.O.C., Cunningham D.S., and Harrison D.J. Altered DNA repair and dysregulation of p53 in IRF-1 null hepatocytes. FASEB J. 12 (1998) 181-188
122. Nozawa H., Oda E., Nakao K., Ishihara M., Ueda S., Yokochi T., Ogasawara K., Nakatsuru Y., Hioki K., Aizawa S., Ishikawa T., Katsuki M., Muto T., Taniguchi T., and Tanaka N. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev. 1-3 (1999) 1240-1245
123. Tanaka N., Ishihara M., Kitagawa M., Harada H., Kimura T., Matsuyama T., Lamphier M.S., Aizawa S., Mak T.W., and Taniguchi T. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77 (1994) 829-839
124. Tanaka N., Ishihara M., Lamphier M.S., Nozawa H., Matsuyama T., Mak T.W., Aizawa S., Tokino T., Oren M., and Taniguchi T. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature 382 (1996) 816-818
125. Moro A., Santos A., Arana M.J., and Perea S.E. Activation of the human p27(Kip1) promoter by IFNalpha 2b. Biochem. Biophys. Res. Commun. 269 (2000) 31-34
126. Sanceau J., Hiscott J., Delattre O., and Wietzerbin J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 19 (2000) 3372-3383
127. Suk K., Chang I., Kim Y.H., Kim S., Kim J.Y., Kim H., and Lee M.S. Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. J. Biol. Chem. 276 (2001) 13153-13159
128. Chow W.A., Fang J.J., and Yee J.K. The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J. Immunol. 164 (2000) 3512-3518
129. Skaar T.C., Bouker K.B., and Clarke R. Interferon regulatory factor-1 (IRF-1) in breast cancer. Proc. Am. Assoc. Cancer Res. 41 (2000) 428
130. Bouker K.B., Skaar T.C., and Clarke R. IRF-1 as a mediator of responsiveness to antiestrogens in breast cancer. Proc. Am. Assoc. Cancer Res. 41 (2000) 427-428
131. Gu Z., Hanfelt J., Hurley C., Xiao H., Gray F., Flessate-Harley D., and Clarke R. High throughput gene expression profiles associated with antiestrogen responsive vs. resistant breast cancer cells. Proc. Am. Assoc. Cancer Res. 40 (1999) 158-159
132. Kim P.K.M., Armstrong M., Liu Y., Yan P., Bucher B., Zuckerbraun B.S., Gambotto A., Billiar T.R., and Yim J.H. IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene 23 (2004) 1125-1135
133. Tu Y., Jerry D.J., Pazik B., and Smith S.S. Sensitivity to DNA damage is a common component of hormone-based strategies for protection of the mammary gland. Mol. Cancer Res. 3 (2005) 435-442
134. Bowie M.L., Dietze E.C., Delrow J., Bean G.R., Troch M.M., Marjoram R.J., and Seewaldt V.L. Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells. Oncogene 23 (2004) 8743-8755
135. Yim J.H., Ro S.H., Lowney J.K., Wu S.J., Connett J., and Doherty G.M. The role of interferon regulatory factor-1 and interferon regulatory factor-2 in IFN-gamma growth inhibition of human breast carcinoma cell lines. J. Interferon Cytokine Res. 23 (2003) 501-511
136. Pizzoferrato E., Liu Y., Gambotto A., Armstrong M.J., Stang M.T., Gooding W.E., Alber S.M., Shand S.H., Watkins S.C., Storkus W.J., and Yim J.H. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res. 64 (2004) 8381-8388
137. Tam W.F., and Sen R. IκB family members function by different mechanisms. J. Biol. Chem. 276 (2001) 7701-7704
138. Yaron A., Hatzubai A., Davis M., Lavon I., Amit S., Manning A.M., Andersen J.S., Mann M., Mercurio F., and Ben Neriah Y. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 396 (1998) 590-594
139. Bours V., Bentires-Alj M., Hellin A.C., Viatour P., Robe P., Delhalle S., Benoit V., and Merville M.P. Nuclear factor-kappa B, cancer, and apoptosis. Biochem. Pharmacol. 60 (2000) 1085-1089
140. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet R.J., and Sledge G.W. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell Biol. 17 (1997) 3629-3639
141. Biswas D.K., Cruz A.P., Gansberger E., and Pardee A.B. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 8542-8547
142. Dickson R.B., and Lippman M.E. Growth factors in breast cancer. Endocr. Rev. 16 (1995) 559-589
143. Clarkson R.W., and Watson C.J. NF-kappaB and apoptosis in mammary epithelial cells. J. Mammary Gland Biol. Neoplasia 4 (1999) 165-175
144. Kim D.W., Sovak M.A., Zanieski G., Nonet G., Romieu-Mourez R., Lau A.W., Hafer L.J., Yaswen P., Stampfer M., Rogers A.E., Russo J., and Sonenshein G.E. Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21 (2000) 871-879
145. Tonko-Geymayer S., and Doppler W. An essential link to mammary cancer?. Nat. Med. 8 (2002) 108-110
146. Cogswell P.C., Guttridge D.C., Funkhouser W.K., and Baldwin Jr. A.S. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19 (2000) 1123-1131
147. Pratt M.A.C., Bishop T.E., White D., Yasvinski G., Menard M., Niu M.Y., and Clarke R. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol. Cell Biol. 23 (2003) 6887-6900
148. Brünner N., Boulay V., Fojo A., Freter C., Lippman M.E., and Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res. 53 (1993) 283-290
149. Hehner S.P., Hofmann T.G., Droge W., and Schmitz M.L. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF- kappa B by targeting the I kappa B kinase complex. J. Immunol. 163 (1999) 5617-5623
150. Zhu Y., Wang A., Liu M.C., Zwart A., Lee R.Y., Gallagher A., Wang Y., Miller W.R., Dixon J.M., and Clarke R. Estrogen receptor alpha (ER) positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures. Int. J. Oncol. 29 (2006) 1581-1589
151. Creighton C.J., Cordero K.E., Larios J.M., Miller R.S., Johnson M.D., Chinnaiyan A.M., Lippman M.E., and Rae J.M. Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol. 7 (2006) R28
152. Zhu Y., Singh B., Hewitt S., Liu A., Gomez B., Wang A., and Clarke R. Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor alpha and progesterone receptor proteins in breast cancer tissue microarrays. Int. J. Oncol. 28 (2006) 67-76
153. de la Fuente A., Bing N., Hoeschele I., and Mendes P. Discovery of meaningful associations in genomic data using partial correlation coefficients. Bioinformatics 20 (2004) 3565-3574
154. Davies M.P., Barraclough D.L., Stewart C., Joyce K.A., Eccles R.M., Barraclough R., Rudland P.S., and Sibson D.R. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int. J. Cancer 123 (2008) 85-88
155. Skaar T.C., Prasad S.C., Sharaeh S., Lippman M.E., Brünner N., and Clarke R. Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 67 (1998) 391-402
156. Kondo T., Minamino N., Nagamura-Inoue T., Matsumoto M., Taniguchi T., and Tanaka N. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 15 (1997) 1275-1281
157. Brankin B., Skaar T.C., Trock B.J., Berris M., and Clarke R. Autoantibodies to numatrin: an early predictor for relapse in breast cancer. Cancer Epidemiol. Biomarkers Prev. 7 (1998) 1109-1115
158. Saura M., Zaragoza C., Bao C., McMillan A., and Lowenstein C.J. Interaction of interferon regulatory factor-1 and nuclear factor kappaB during activation of inducible nitric oxide synthase transcription. J. Mol. Biol. 289 (1999) 459-471
159. Drew P.D., Franzoso G., Becker K.G., Bours V., Carlson L.M., Siebenlist U., and Ozato K. NF kappa B and interferon regulatory factor 1 physically interact and synergistically induce major histocompatibility class I gene expression. J. Interferon Cytokine Res. 15 (1995) 1037-1045
160. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310